From the Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Pancreas. 2021 Apr 1;50(4):469-493. doi: 10.1097/MPA.0000000000001792.
This manuscript is the result of the North American Neuroendocrine Tumor Society consensus conference on the medical management and surveillance of metastatic and unresectable pheochromocytoma and paraganglioma held on October 2 and 3, 2019. The panelists consisted of endocrinologists, medical oncologists, surgeons, radiologists/nuclear medicine physicians, nephrologists, pathologists, and radiation oncologists. The panelists performed a literature review on a series of questions regarding the medical management of metastatic and unresectable pheochromocytoma and paraganglioma as well as questions regarding surveillance after resection. The panelists voted on controversial topics, and final recommendations were sent to all panel members for final approval.
这份手稿是北美神经内分泌肿瘤学会于 2019 年 10 月 2 日和 3 日举行的关于转移性和不可切除的嗜铬细胞瘤和副神经节瘤的医学管理和监测的共识会议的结果。小组成员由内分泌学家、肿瘤内科医生、外科医生、放射科医生/核医学医师、肾病学家、病理学家和放射肿瘤学家组成。小组成员对一系列关于转移性和不可切除的嗜铬细胞瘤和副神经节瘤的医学管理以及关于切除后监测的问题进行了文献回顾。小组成员就有争议的问题进行了投票,最终建议发送给所有小组成员进行最终批准。